Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant P.1, also known as variant Gamma originally discovered in Brazil, and contains all ten P.1 mutations, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant P.1, also known as variant Gamma originally discovered in Brazil, and contains all ten P.1 mutations, as listed below. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y (found in the RBD domain of some variants of concern). The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein contains three mutations of interest K417T, E484K and N501Y (found in the RBD domain of some variants of concern). The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.1, also known as variant Kappa, originally identified in India. It contains mutations G142D, E154K, L452R, E484Q, D614G, and P681R. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.1, also known as variant Kappa, originally identified in India. It contains mutations G142D, E154K, L452R, E484Q, D614G, and P681R. The construct also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.617.2 also known as variant Delta originally identified in India, and contains mutations T19R, G142D, R158G, L452R, T478K D614G and P681R. It was constructed with a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Description: SARS-CoV-1 monoclonal Spike S1 VHH neutralizing antibody, a.a. 1-127(full length), with C-terminal Avi-Tag fused to the Fc portion of Human IgG1, expressed in a HEK293 cell expression system. MW = 43 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%. VHHs are single-domain antibodies from camelids.

Description: Since April 2012, cases of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have been identified in the following countries: Saudi Arabia, Qatar, Jordan, the United Arab Emirates, Oman, Kuwait, Yemen, Lebanon, Iran, Algeria, the United Kingdom, France, Italy, Greece, Germany, the Netherlands, Austria, Tunisia, Egypt, Malaysia, Turkey and the United States of America. Coronaviruses are the cause of the common cold, SARS (severe acute respiratory syndrome) and other severe illnesses with high mortality rates, all are classified into coronavirus family. MERS-CoV is a new type of SARS found in the coronavirus family causing severe pneumonia with sudden and serious respiratory illness with high mortality rates as well. Since January 27th 2015, the WHO has reported 956 human cases, including 351 deaths. More cases of the new coronavirus strain are expected. Like in other coronaviruses, large surface spike glycoprotein is a central structural protein of this virus; it is located above the virion surface to bind and enter into the target cell. Spike protein has 2 domains- S1 and S2. The S1 domain is responsible for cellular tropism and interaction with target cell, while the S2 domain is responsible for membrane fusion. The C-terminal of S1 domain contains a receptor binding domain, and is also a potential target for vaccine development and an antigen for diagnosis.

Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.